HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat.

Abstract
Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS). Intravenous immunoglobulins (IVIg) are an effective treatment for GBS, but their mechanism of action is not well understood. Here we tested whether IVIg treatment, a potent modulator of proinflammatory assaults, reduces inflammation in EAN. The evaluation of IVIg treatment failed to demonstrate a salutary effect in different models of EAN. IVIg appears not to suppress the acute inflammatory insult on the peripheral nerve, but may have beneficial long-term effects not looked for in the present investigation.
AuthorsU Enders, K V Toyka, H P Hartung, R Gold
JournalJournal of neuroimmunology (J Neuroimmunol) Vol. 76 Issue 1-2 Pg. 112-6 (Jun 1997) ISSN: 0165-5728 [Print] Netherlands
PMID9184640 (Publication Type: Journal Article)
Chemical References
  • Immunoglobulins, Intravenous
Topics
  • Animals
  • Female
  • Immunoglobulins, Intravenous (therapeutic use)
  • Neuritis, Autoimmune, Experimental (therapy)
  • Polyradiculoneuropathy (therapy)
  • Rats
  • Rats, Inbred Lew

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: